Commentary|Articles|October 30, 2023

Slash Killers and Their Psychiatric Issues

Author(s)Fernando Espí Forcén, MD, PhD

Are you ready for Halloween? Who is your favorite slash killer of the horror genre and which psychiatric disorder could he meet criteria for?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Should Solitude Be a Psychiatric Value?

ByRonald W. Pies, MD

October 23rd 2025

Preliminary Report on Dangers of AI Chatbots

ByAllen Frances, MD,Luciana Ramos

October 7th 2025

“By His Own Hand”: Socrates’ Suicide as an Affirmative Choice, A Reply to Rev. Christopher Dreisbach, PhD

ByVincenzo Di Nicola, MPhil, MD, PhD, FCAHS, DLFAPA, DFCPA, FACPsych, FRSC

October 1st 2025

Artificial Intelligence Will Never Replace Psychiatry—But It Will Try to Destroy It

ByDaniel Morehead, MD

September 18th 2025

No, Antidepressants Do Not Provoke Mass Shootings

ByJames L. Knoll IV, MD,Ronald W. Pies, MD

September 12th 2025

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Slash Killers and Their Psychiatric Issues

Newsletter

Related Content

Should Solitude Be a Psychiatric Value?

Preliminary Report on Dangers of AI Chatbots

“By His Own Hand”: Socrates’ Suicide as an Affirmative Choice, A Reply to Rev. Christopher Dreisbach, PhD

Artificial Intelligence Will Never Replace Psychiatry—But It Will Try to Destroy It

No, Antidepressants Do Not Provoke Mass Shootings

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Use of TMS in Treatment of Depression, Discussion With Rachel Rohaidy, MD

Glutamatergic Pathways in Major Depressive Disorder: Insights From Juan D. Oms, MD, FAPA

Lecanemab or Lithium? Compare Benefits, Risks, and Dose

Tolerance to Stimulant Medications in the Treatment of Children With ADHD

Vagus Nerve Stimulation in Treatment Resistant Depression: New Lines of Thinking